Literature DB >> 17055191

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Hannu Alho1, David Sinclair, Erkki Vuori, Antti Holopainen.   

Abstract

Buprenorphine (Subutex) is widely abused in Finland. A combination of buprenorphine plus naloxone (Suboxone) has been available since late 2004, permitting a comparison of the abuse of the two products among untreated intravenous (IV) users. A survey was distributed to attendees at a Helsinki needle exchange program over 2-weeks in April, 2005, At least 30% were returned anonymously. Survey variables included: years of prior IV opioid abuse, years of buprenorphine abuse, frequency, dosage, route of administration and reasons for use, concomitant IV abuse of other substances and amount paid on the street for both buprenorphine and buprenorphine+naloxone. Buprenorphine was the most frequently used IV drug for 73% of the respondents. More than 75% said they used IV buprenorphine to self-treat addiction or withdrawal. Most (68%) had tried the buprenorphine+naloxone combination IV, but 80% said they had a "bad" experience. Its street price was less than half that of buprenorphine alone. The buprenorphine+naloxone combination appears to be a feasible tool, along with easier access to addiction treatment, for decreasing IV abuse of buprenorphine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055191     DOI: 10.1016/j.drugalcdep.2006.09.012

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  54 in total

1.  Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Authors:  Clementina Stimolo; Valentina Del Favero; Giancarlo Zecchinato; Roberto Buson; Davide Cusin; Patrizia Pellachin; Pamela Simonetto
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Authors:  Fernanda Magnelli; Lorita Biondi; Roberto Calabria; Angelo Fiore; Eugenio Peluso; Domenico Vonella; Amerigo Giuseppe Rota
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.

Authors:  Enrico Moratti; Hamid Kashanpour; Tiziana Lombardelli; Maria Maisto
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Authors:  Franco Montesano; Domenico Zaccone; Egidio Battaglia; Felice Genco; Vincenzo Mellace
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Authors:  Patrizia Amato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 6.  Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Carmen Walter; Claudia Knothe; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 7.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

9.  Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Authors:  M A Huestis; E J Cone; S O Pirnay; A Umbricht; K L Preston
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

10.  Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Authors:  George E Woody; Sabrina A Poole; Geetha Subramaniam; Karen Dugosh; Michael Bogenschutz; Patrick Abbott; Ashwin Patkar; Mark Publicker; Karen McCain; Jennifer Sharpe Potter; Robert Forman; Victoria Vetter; Laura McNicholas; Jack Blaine; Kevin G Lynch; Paul Fudala
Journal:  JAMA       Date:  2008-11-05       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.